NeuroScientific Biopharmaceuticals has announced that US regulators have largely endorsed its plans for a Phase 2 trial of a stem cell therapy in people with Crohn's disease who have not responded to existing treatments.
The company said it still needs to resolve one manufacturing issue before the study can begin. It said the US Food and Drug Administration had responded favourably to six of the seven questions the company put to it at a Pre-Investigational New Drug meeting about its product StemSmart.
It said the FDA agreed with the proposed trial design in refractory Crohn's disease. The agency also accepted that the existing evidence from people already treated with StemSmart was sufficient, so no further nonclinical studies would be needed. It also found the company's proposed release testing strategy acceptable.
The unresolved question concerns the manufacturing control strategy, which must ensure the product is free from viral contamination. NeuroScientific said it agreed with the FDA's feedback and was implementing the required testing "with minimal impact to timelines".
The company also passed on comments from its own regulatory consultants. It said they had described the FDA's response to its briefing package as very positive and told the company it was fortunate to be granted a face-to-face meeting, because the agency had been very selective in granting these meetings in lieu of written responses in recent months.
Chief executive Nathan Smith said the result reflected the work done to prepare the product for clinical testing. "The excellent outcome from our Pre-IND meeting with the US FDA demonstrates the exceptional work the NSB team has done to ensure StemSmart is suitable for use in the planned Phase 2 clinical trial in treatment-resistant Crohn's disease in the US. The achievement of another pivotal milestone in NSB's clinical development for our patented StemSmart technology platform takes us one step closer to providing a potential treatment option for patients with this debilitating disease."
StemSmart is made from mesenchymal stem cells taken from adult donors' bone marrow. It is produced using a patented manufacturing process developed at Royal Perth Hospital, which is designed to improve therapeutic activity and clinical response and to modulate the abnormal immune responses often seen in severe chronic inflammatory conditions.
NeuroScientific acquired the technology in 2025. It says early indications from an earlier Phase 2 trial in refractory Crohn's disease suggest the cells are potent, efficacious and safe. The company plans further Phase 2 trials to assess safety and preliminary efficacy in refractory or fistulising Crohn's disease, aimed at patients for whom current therapies remain inadequate.